Attorney Docket No. PO-

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: SERIAL NO:

TITLE:

CAMPBELL, JOY M. 09/973,283

Group Art Unit: 1614 Examiner:

FILED:

October 9, 2001

Confirmation No: METHODS AND COMPOSITIONS FOR MODULATING THE IMMUN

SYSTEM OF ANIMALS

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BEFORE MAILING DATE OF EITHER A FINAL ACTION OR NOTICE OF ALLOWANCE (37 C.F.R. § 1.97(c))

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir-

This information disclosure statement is being filed before the mailing date of either a final action under § 1.113 or a notice of allowance under § 1.311, whichever occurs first.

Attached are Forms PTO/SB/08A and 08B (formerly Form PTO-1449) listing the relevant art known to the applicant herein. Copies of the listed references are enclosed. The Examiner is requested to consider the references and make them of record.

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose. Legible copies of all items listed in Forms PTO/SB/08A and 08B (formerly Form PTO-1449) accompany this information statement.

No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of

CERTIFICATE OF MAILING

I hereby certify that the above correspondence was mailed to the Assistant Commissioner for Patents, Washington, D.C. 20231, as First Class mail, postage prepaid, this 1st day of November, 2002.

designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. (Notice of January 9, 1992, 1135 O.G. 13-25, at 25.)

Respectfully submitted,

HEIDI S. NEBBL, Reg. No. 37,719

McKEE, VOORHEES & SEASE, P.L.C. 801 Grand Avenue, Suite 3200

Des Moines, Iowa 50309-2721

Phone No. (515) 288-3667 Fax No. (515) 288-1338

CUSTOMER NO: 22885

- mlw -

Attorneys of Record



Form PTO/SA08B (10-01) Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449A/PTO Complete if Known Application Number 09/973 283 INFORMATION DISCLOSURE Filing Date **OCTOBER 9, 2001** First Named Inventor CAMPBELL, JOY M., et al. STATEMENT BY APPLICANT Art Unit (Use as many sheets as necessary) Examiner Name Sheet Attorney Docket Number 1 of P04854US1

			U.S. PA	TENT DOCUMENTS	
Examiner Initials *	Cite No.1	Document Number Number - Kind Code ² (if known	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US- 4,748,157	05-31-1988	Iwai et al.	
	2	US- 4,816,561	03-28-1989	Todaro	
	3	US- 4,849,404	07-18-1989	Iwai et al.	
	4	US- 5,389,664	02-14-1995	Baile et al.	. 57
		US- RE 33,565	04-02-1991	Stolle et al.	TIME TO THE TOTAL
		US- 4,732,757	03-22-1988	Stolle et al.	HOE N
		US-			NOW O
		US-			3 7 10
		US-			1 2
		US-			1 2 7
		US-			1907
		US-			2 2
		US-		7.0	7002 100012300
		US-			-
		US-			·

		FOREIG	N PATENT DOC	UMENTS		
Examiner Initials *	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Occument	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	5	EPO/0 064 210	11-10-1982	Cutter Laboratories		_
	v	WO 00/62806	10/26/2000	Weisbart, Richard		
	-	GB 2013691	08/15/1979	Stolle Res & Dev		_
		JP 54113425	08/15/1979	Stolle Res & Dev		_
		JP 59070621	04/21/2984	Sugizaki Tetsuzou		
						_
						_

Examiner	Date
Signature	Considered
	Considered

*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in

"EAAMINEK: Initial in reterence considered windered or not cation is in conformance with MHEM (soll). Unaw line through oilation in not in conformance and not considered. Include copy of this form with next communication to applicant as https://www.usdn.oog or NPEP 001.04. * Enter Office that Issued the document, by the wolveter code (NPFO Standard ST.a.). *For Jacquares patient documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as influenced on the text of the patent document. *Kind of document by the appropriate symbols as influenced on the text of the standard on the text of the standard of the patent document. *Kind of document by the appropriate symbols as influenced on the standard of the standard document under WIPO Standard ST. 16 if possible.

OCUMENT Univer VIII-V CONTINUED TO IN UNIVERSITY APPLICATION TO PLACE A CHARGE ATTEMPT AND THE ACT OF THE ACT



Form PTOSEGREE (10.01)
Approved for use through 1021/2020, 0440 0854 1030

Approved for use through 1021/2020, 0440 0854 1030

U.S. Pedent and Trademark Office U.S. D'EPARTMENT OF COMMERCE
Under the Paperverik Reduction Act of 1995, no persons are required to respond to a collection of information unless at contrale a valid office confidence of information unless at contrale a valid office confidence of information unless at contrale a valid office confidence of information unless at contrale a valid office confidence of information unless at contrale a valid office of information unless at contrale a valid office of information unless at contrale a valid of information unless at valid of i

Substitute for form 1449B/PTO Complete if Known Application Number 09/973,283 INFORMATION DISCLOSURE Filing Date October 9, 2001 STATEMENT BY APPLICANT First Named Inventor CAMPBELL, JOY M. et al. Group Art Unit 1614 (Use as many sheets as necessary) Examiner Name Sheet 2 of Attorney Docket Number P04854US1

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), tills of the article (when appropriate), tills of the item (tools, magazine, journal, serial, symposium, catelog, etc.), date, page(s), volume-issue number(s), publisher, oily and/or country where published.	T2
	6	WILLIAMS, E.W., Bovine IgG in the Serum of adult rats after oral administration, IRCS Med. Sci.:Libr. Compend, 1977	
	7	ShowTec Survivor with Solutein.htm, September 29, 2002. PP.1-3	
	8	FRANK MOREY, Countryside Feed Notes, January 2002, p.1, Hillsboro, KS	
	9	South Central Nutritional Services, Wells, MN	
	10	RHOADES, et al., Gastroenterology 118, No. 4, 2000	
	11	ELAINE HUNT, et al., Oral Bovine Serum Concentrate Improves Cryptosporidial in Calves, North Carolina State University College of Veterinary Medicine, Vol.51, No.3, 2002	
	12	The FASEB Journal, EB 2000, San Diego, CA, March 15, 2000, Volume 14, No.4	
	13	B.S. BORG et al., Effects of a Water Soluble Plasma Protein on Weanling Pig Performance and Health With and Without Escherichia coli Challenge, American Protein Corporation, Ames, IA, Allen D. Leman Swine Conference, Sept. 17-21, 1999	
	14	J.M. CAMPBELL et al., Benefits Derived from Swine Dites Containing Plasma in Escherichia coll Challenged Pigs, Amertican Association of Swine Practitioners, 2000, pp.129-132	
		PECA	
		TECH NOVE TO	
		CENTER 200	2 04
		600/297	<u></u>

Signature		Date Considered	
* EXAMINER: Initial if refe	erence considered whether or not citation is in conformance	with MDED con	Deput line shows by state of the

conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Burden Nour Statement. This form is estimated to bite. 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are requised to complete this form should be sent to the Chell Information Officer, U.S. Patent and Trademark. Office. Washington, DC 20231 DO NOT SEND FEES OR COMPLETED PORMS TO THIS ADDRESS. SEND TO. Assistant.